Cargando…

Direct and indirect effects of SARS-CoV-2 pandemic in subjects with familial hypercholesterolemia: A single lipid-center real-world evaluation

Detalles Bibliográficos
Autores principales:	Scicali, R., Ferrara, V., Piro, S., Purrello, F., Di Pino, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425765/ http://dx.doi.org/10.1016/j.atherosclerosis.2022.06.545

Ejemplares similares

Direct and Indirect Effects of SARS-CoV-2 Pandemic in Subjects with Familial Hypercholesterolemia: A Single Lipid-Center Real-World Evaluation
por: Scicali, Roberto, et al.
Publicado: (2021)

Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting
por: Scicali, Roberto, et al.
Publicado: (2021)

May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
por: Scicali, Roberto, et al.
Publicado: (2020)

Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience
por: Scicali, Roberto, et al.
Publicado: (2020)

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
por: Palumbo, Marcella, et al.
Publicado: (2022)

Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units
por: Scicali, Roberto, et al.
Publicado: (2022)

Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation
por: Scicali, Roberto, et al.
Publicado: (2019)

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
por: Toscano, Arianna, et al.
Publicado: (2022)

Direct Effects of D-Chiro-Inositol on Insulin Signaling and Glucagon Secretion of Pancreatic Alpha Cells
por: Filippello, Agnese, et al.
Publicado: (2020)

Indirect Effects of the COVID-19 Pandemic on In-Hospital Outcomes among Internal Medicine Departments: A Double-Center Retrospective Study
por: Di Marco, Maurizio, et al.
Publicado: (2023)

Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice
por: Bosco, Giosiana, et al.
Publicado: (2023)

Impact of Familial Hypercholesterolemia Diagnosis in Real-World Data
por: Harada-Shiba, Mariko
Publicado: (2023)

Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy
por: Urbano, Francesca, et al.
Publicado: (2019)

Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
por: Marchisello, Simona, et al.
Publicado: (2019)

Familial Hypercholesterolemia: The Lipids or the Genes?
por: Fahed, Akl C, et al.
Publicado: (2011)

Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD
por: Di Mauro, Stefania, et al.
Publicado: (2021)

An update on lipid apheresis for familial hypercholesterolemia
por: Taylan, Christina, et al.
Publicado: (2022)

Achilles tendon ultrasonography in familial hypercholesterolemia: A sub‐study of the LIpid transPort disorders Italian GEnetic Network (LIPIGEN)
por: Baragetti, Andrea, et al.
Publicado: (2021)

Aortic Valvular Disease in Elderly Subjects with Heterozygous Familial Hypercholesterolemia: Impact of Lipid-Lowering Therapy
por: Marco-Benedí, Victoria, et al.
Publicado: (2019)

Usefulness of Lipid Apheresis in the Treatment of Familial Hypercholesterolemia
por: Lui, Matthew, et al.
Publicado: (2014)

Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat β-Cells. Direct Effect of Oxidative Stress
por: Urbano, Francesca, et al.
Publicado: (2017)

Chronic Exposure to Palmitate Impairs Insulin Signaling in an Intestinal L-cell Line: A Possible Shift from GLP-1 to Glucagon Production
por: Filippello, Agnese, et al.
Publicado: (2018)

1 h Postload Glycemia Is Associated with Low Endogenous Secretory Receptor for Advanced Glycation End Product Levels and Early Markers of Cardiovascular Disease
por: Di Pino, Antonino, et al.
Publicado: (2019)

Author Correction: Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat β-Cells. Direct Effect of Oxidative Stress
por: Urbano, Francesca, et al.
Publicado: (2020)

A Real-World Experience of Clinical, Biochemical and Genetic Assessment of Patients with Homozygous Familial Hypercholesterolemia
por: Di Taranto, Maria Donata, et al.
Publicado: (2020)

Management of Familial Hypercholesterolemia: A Review of the Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia
por: Robinson, Jennifer G.
Publicado: (2013)

Pharmacogenomics Variability of Lipid-Lowering Therapies in Familial Hypercholesterolemia
por: Hindi, Nagham N., et al.
Publicado: (2021)

Controlling Nutritional Status (CONUT) Score as a Potential Prognostic Indicator of In-Hospital Mortality, Sepsis and Length of Stay in an Internal Medicine Department
por: Miano, Nicoletta, et al.
Publicado: (2023)

Long-Term Efficacy and Safety of Evinacumab in Patients with Homozygous Familial Hypercholesterolemia: Real-World Clinical Experience
por: Stefanutti, Claudia, et al.
Publicado: (2022)

High Glucose Exposure Impairs L-Cell Differentiation in Intestinal Organoids: Molecular Mechanisms and Clinical Implications
por: Filippello, Agnese, et al.
Publicado: (2021)

Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study
por: Yamashita, Shizuya, et al.
Publicado: (2022)

Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan
por: Teramoto, Tamio, et al.
Publicado: (2018)

Diabetes and Familial Hypercholesterolemia: Interplay between Lipid and Glucose Metabolism
por: González-Lleó, Ana M., et al.
Publicado: (2022)

Familial Hypercholesterolemia
por: Baruah, Dibya Kumar
Publicado: (2021)

Real-World Data to Identify Hypercholesterolemia Patients on Suboptimal Statin Therapy
por: Kajinami, Kouji, et al.
Publicado: (2019)

Genetically confirmed familial hypercholesterolemia in outpatients with hypercholesterolemia
por: Wang, Xu, et al.
Publicado: (2018)

Identification of a New RNA and Protein Integrated Biomarker Panel Associated with Kidney Function Impairment in DKD: Translational Implications
por: Scamporrino, Alessandra, et al.
Publicado: (2023)

Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor
por: Jarauta, Estíbaliz, et al.
Publicado: (2020)

Real-World Evaluation of Direct and Indirect Economic Burden Among Endometriosis Patients in the United States
por: Soliman, Ahmed M., et al.
Publicado: (2018)

Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting
por: Mahzari, Moeber, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0mrmjfpq8nlddknt30sa3itsis